Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143088 | 0.90 | MEN1 (0.49) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL3143629 | 0.89 | MEN1 (0.48) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL2089435 | 0.83 | PRKDC (0.51) | MAPTPKMPRKDCALDH1A1HTT | |
| SCHEMBL2088134 | 0.81 | MAPT (0.48) | MAPTPRKDCHTTMEN1LMNA | |
| SCHEMBL23032760 | 0.78 | MAPT (0.50) | MAPTPRKDCALDH1A1THRBBRD4 | |
| SCHEMBL20945305 | 0.78 | ALDH1A1 (0.47) | MAPTPKMALDH1A1HTTMEN1 | |
| SCHEMBL30595807 | 0.78 | MAPT (0.50) | MAPTPRKDCALDH1A1THRBBRD4 | |
| SCHEMBL2086265 | 0.77 | PRKDC (0.55) | MAPTPKMPRKDCALDH1A1HTT | |
| SCHEMBL3133550 | 0.77 | MAPT (0.56) | MAPTPKMPRKDCTHRBHTT | |
| SCHEMBL4890072 | 0.76 | PRKDC (0.56) | MAPTPKMPRKDCHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2119719-A1 | THIAZEPINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004221-A1 | THIAZEPINE DERIVATIVE | HSD11B1, HSD17B1, HSD3B1 | MAPT 4734/4885PKM 1696/4885PRKDC 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.